Fast Magnetic Resonance Imaging With Contrast for Soft Tissue Sarcoma Viability
- 1 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 397 (397) , 212-227
- https://doi.org/10.1097/00003086-200204000-00026
Abstract
Because dynamic (fast) contrast-enhanced magnetic resonance imaging with its temporal resolution allows evaluation of contrast kinetics of soft tissue sarcomas, its efficacy for defining viable tumor in these neoplasms was studied for three applications: biopsy localization, chemotherapeutic response, and differentiation between recurrence and inflammation after treatment. After conventional T1-weighted and T2-weighted magnetic resonance sequences to localize the lesion, patients had dynamic contrast-enhanced magnetic resonance imaging with fast and ultrafast sequences and postprocessing techniques (subtraction, time-intensity curves, and parametric color-encoding). In 10 of 40 patients, dynamic imaging more precisely defined the most malignant foci of tumor for biopsy than conventional magnetic resonance imaging. After chemotherapy, dynamic imaging distinguished 11 good responders from 21 poor responders. In followup of 196 patients, dynamic imaging detected 42 early enhancing recurrences and excluded recurrent tumor in six late enhancing pseudotumors. Dynamic imaging can differentiate viable tumor from nonviable tumor and inflammation by showing two temporally different phases of contrast enhancement: an early phase correlative with viable tumor at histologic examination, and a late phase when all tissues enhance simultaneously and may be indistinguishable. By showing tumor viability, dynamic contrast-enhanced magnetic resonance imaging can help define biopsy sites, chemotherapeutic response, and presence or absence of recurrences and therefore affect the initial evaluation, treatment, and followup of patients with soft tissue sarcomas.Keywords
This publication has 45 references indexed in Scilit:
- Biopsy of Musculoskeletal TumorsPublished by Wolters Kluwer Health ,1999
- Evidence for using adjuvant chemotherapy as standard treatment of soft tissue sarcomaSeminars in Radiation Oncology, 1999
- Major developments in the understanding and treatment of soft-tissue sarcomas in adultsCurrent Opinion in Oncology, 1998
- Variable management of soft tissue sarcoma: Regional audit with implications for specialist careBritish Journal of Surgery, 1997
- The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremityJournal of Surgical Oncology, 1997
- Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging.Radiology, 1992
- Factor Analysis of Dynamic Magnetic Resonance Imaging in Predicting the Response of Osteosarcoma to ChemotherapyInvestigative Radiology, 1992
- Soft-tissue sarcomas: use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging.Radiology, 1992
- New directions in the development of MR imaging contrast media.Radiology, 1992
- Intravenous Bolus of 125I Labeled Meglumine DiatrizoateActa Radiologica. Diagnosis, 1977